Clinical and pharmacokinetic/dynamic outcomes of prolonged infusions of beta-lactam antimicrobials: An overview of systematic reviews
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Objective: This overview of reviews aims to map and compare of objectives, methods, and findings of existing systematic reviews to develop a greater understanding of the information available about prolonged beta-lactam infusions in hospitalized patients with infection. Design: Overview of systematic reviews. Data sources: Medline, Embase, PROSPERO and the Cochrane Library were systematically searched from January, 1990 to June, 2019 using a peer reviewed search strategy. Grey literature was also searched for relevant reviews. Eligibility criteria for selecting reviews: Systematic reviews were sought that compared two or more infusion strategies for intravenous beta-lactam antimicrobials and report clinical cure or mortality. Populations of included reviews were restricted to hospitalized patients with infection, without restrictions on age, infection type, or disease. Data extraction and analysis: Abstract screening, data extraction, quality and risk of bias assessment were conducted by two independent reviewers. Overlap between reviews was assessed using a modified corrected covered area. Overview findings are reported in accordance with Cochrane’s recommendation for overview conduct. Clinical outcomes extracted included survival, clinical cure, treatment failure, microbiological cure, length of stay, adverse events, cost, and emergence of resistance. Results: The search strategy identified 3327 unique citations from which 21 eligible reviews were included. Reviews varied by population, intervention and outcomes studied. Between reviews, overlap of primary studies was generally high, methodologic quality generally low and risk of bias variable. Nine of 14 reviews that quantitatively evaluated mortality and clinical cure identified a benefit with prolonged infusions of beta lactams when compared with intermittent infusions. Evidence of mortality and clinical cure benefit was greater among critically ill patients when compared to less sick patients and lower in randomized controlled trials when compared with observational studies. Conclusions: Findings from our review demonstrate a consistent and reproducible lack of harm with prolonged infusions of beta-lactam antibiotics with variability in effect size and significance of benefits. Despite 21 systematic reviews addressing prolonged infusions of beta-lactams, this overview supports the continued need for a definitive systematic review given variability in populations, interventions and outcomes in the current systematic reviews. Subsequent systematic reviews should have more rigorous and transparent methods, only include RCTs and evaluate the proposed benefits found in various subgroup-analyses—i.e. high risk of mortality. Trial registration: Prospero registry, CRD42019117118.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Fig 7 Effect of prolonged versus intermittent infusions of beta-lactam antimicrobials on clinical cure. *Lee 2017 –Did not report event rates. RR was therefore not converted to OR. **Roberts 2016 –individual patient data meta-analysis. ***Chant 2013 –reported treatment failure. RR = 0.60 [0.40–0.87], I2 = 69%. Results were inverted to represent clinical cure or success.](https://figures.cochat.ai/paper-figures/b6a76ab044a84298af1a15ee707e2a44/clinical-and-pharmacokinetic-dynamic-outcomes-of-prolonged-infusions-of-beta-figure-7.jpg)














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“when low overlap was found between reviews with inconsistent and discordant findings, discrepancies were most often attributed to differences in scope or differences in dates of review publication.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Twenty-one reviews involving 71 primary studies were included.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thabet et al. found that overlap was moderate to high for each outcome and percentage of unique references ranged from 38 to 78%.”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
In the citing paper
“when two reviews had similar findings and low overlap for a particular outcome, the results of the reviews could be trusted despite differences in PICO scope (i.e. different populations or beta-lactams) or differences in dates of publication”
From Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews (2021) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636 · cited 1×
“Quality assessment of each included review was conducted using the AMSTAR-2 tool (Assessing the Methodological Quality of Systematic Reviews), and risk of bias of assessments were performed using with the ROBIS tool (Risk of Bias in Systematic Reviews); all assessments were performed by one reviewer (PT) and verified…”
MethodAngus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503
PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
ROBIS: A new tool to assess risk of bias in systematic reviews was developed
Whiting, P., Savović, J., Higgins, J. P. T., Caldwell, D. M., Reeves, B. C., Shea, B., Davies, P., Kleijnen, J., & Churchill, R. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.06.005 · Cited by 2,272
Increasing value and reducing waste in research design, conduct, and analysis
Ioannidis, J. P. A., Greenland, S., Hlatky, M. A., Khoury, M. J., Macleod, M. R., Moher, D., Schulz, K. F., & Tibshirani, R. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62227-8 · Cited by 1,597
Reducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319
Systematic review finds overlapping reviews were not mentioned in every other overview
Pieper, D., Antoine, S.-L., Mathes, T., Neugebauer, E. A. M., & Eikermann, M. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.11.007 · Cited by 1,318
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543 · cited 1×
“Growing concern as to generalizability of this target has been expressed, and there is a mounting evidence supporting a target of 100% time above the MIC for critically ill patients and those with life threatening infections with resistant organisms [13, 14].”
BackgroundLodise, T. P., Lomaestro, B., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510590 · Cited by 527
Roberts, J. A., Abdul-Aziz, M.-H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0024oc · Cited by 379 · cited 15×
“Importantly six reviews did not perform subgroup analyses base on study design as these exclusively included RCTs [16, 23, 26, 27, 29, 48].”
BackgroundResultInfluentialInsufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
Taccone, F. S., Laterre, P.-F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., De Backer, D., Layeux, B., Wallemacq, P., Vincent, J.-L., et al. (2010) · Critical Care · doi:10.1186/cc9091 · Cited by 369
Vardakas, K. Z., Voulgaris, G. L., Maliaros, A., Samonis, G., & Falagas, M. E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30615-1 · Cited by 327
Falagas, M. E., Tansarli, G. S., Ikawa, K., & Vardakas, K. Z. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis857 · Cited by 283
Bougioukas, K. I., Liakos, A., Tsapas, A., Ntzani, E., & Haidich, A.-B. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.10.002 · Cited by 251 · cited 2×
“Overview findings are reported descriptively by outcome, following Cochrane’s recommendation for overview conduct and the PRIO-harms checklist (S2 Fig) [37, 40].”
MethodSeyler, L., Cotton, F., Taccone, F. S., De Backer, D., Macours, P., Vincent, J.-L., & Jacobs, F. (2011) · Critical Care · doi:10.1186/cc10257 · Cited by 232
A systematic review on clinical benefits of continuous administration of β-lactam antibiotics*
Roberts, J. A., Webb, S., Paterson, D., Ho, K. M., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a0054d · Cited by 225
Martinez, M. N., Papich, M. G., & Drusano, G. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05360-11 · Cited by 215
Sepsis and Septic Shock: Current Treatment Strategies and New Approaches
Halici, Z., Cadirci, E., Polat, G., & Ugan, R. A. (2019) · The Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2017.17062 · Cited by 192
De Waele, J. J., Lipman, J., Akova, M., Bassetti, M., Dimopoulos, G., Kaukonen, M., Koulenti, D., Martin, C., Montravers, P., Rello, J., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3403-8 · Cited by 178
Chytra, I., Stepan, M., Benes, J., Pelnar, P., Zidkova, A., Bergerova, T., Pradl, R., & Kasal, E. (2012) · Critical Care · doi:10.1186/cc11405 · Cited by 174
Vincent, J.-L., & Abraham, E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1604oe · Cited by 167
Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections
Bauer, K. A. A., West, J. E., O’Brien, J. M., & Goff, D. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02365-12 · Cited by 161
Continuous infusion of β-lactam antibiotics in severe infections: a review of its role
Roberts, J. A., Paratz, J., Paratz, E., Krueger, W. A., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.002 · Cited by 150 · cited 7×
“Of these, three reviews [21, 28, 52] described the findings of one study [60] that attributed serious adverse to 6 patients with complicated intra-abdominal infections randomized to receive a continuous infusion of piperacillin/tazobactam including Clostridium difficile colitis, renal failure, confusion, tachycardia,…”
BackgroundInfluentialLau, W. K., Mercer, D., Itani, K. M., Nicolau, D. P., Kuti, J. L., Mansfield, D., & Dana, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00329-06 · Cited by 139
Rhodes, N. J., Liu, J., O’Donnell, J. N., Dulhunty, J. M., Abdul-Aziz, M. H., Berko, P. Y., Nadler, B., Lipman, J., & Roberts, J. A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002836 · Cited by 130
Grant, E. M., Kuti, J. L., Nicolau, D. P., Nightingale, C. H., & Quintiliani, R. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.471.33665 · Cited by 126
Continuous infusion versus intermittent administration of meropenem in critically ill patients
Thalhammer, F., Traunmuller, F., El Menyawi, I., Frass, M., Hollenstein, U. M., Locker, G. J., Stoiser, B., Staudinger, T., Thalhammer-Scherrer, R., & Burgmann, H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.523 · Cited by 125
Yu, Z., Pang, X., Wu, X., Shan, C., & Jiang, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201667 · Cited by 121
Muller, A. E., Punt, N., & Mouton, J. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks468 · Cited by 120
Teo, J. Q.-M., Liew, Y., Lee, W., & Kwa, A. L. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.027 · Cited by 106
Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., Howard, S. J., Neely, M. N., & Hope, W. W. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00867-13 · Cited by 94
Tamma, P. D., Putcha, N., Suh, Y. D., Van Arendonk, K. J., & Rinke, M. L. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-181 · Cited by 85
Yang, H., Zhang, C., Zhou, Q., Wang, Y., & Chen, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116769 · Cited by 85
Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis
Shabaan, A. E., Nour, I., Eldegla, H., Nasef, N., Shouman, B., & Abdel‐Hady, H. (2016) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001445 · Cited by 77
Optimizing Antimicrobial Therapy in Sepsis and Septic Shock
Kumar, A. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.08.004 · Cited by 76
Zhao, H., Gu, J. P., Lyu, J., Liu, D., Wang, Y., Liu, F., Zhu, F., & An, Y. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.205859 · Cited by 68
Gao, H., Evans, T. W., & Finney, S. J. (2008) · Critical Care · doi:10.1186/cc6862 · Cited by 67
OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM
Kuti, J. L. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.08.001 · Cited by 62
Chant, C., Leung, A., & Friedrich, J. O. (2013) · Critical Care · doi:10.1186/cc13134 · Cited by 61
Lee, Y. R., Miller, P. D., Alzghari, S. K., Blanco, D. D., Hager, J. D., & Kuntz, K. S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0439-5 · Cited by 59
Pharmacodynamic optimization of β-lactams in the patient care setting
Nicolau, D. P. (2008) · Critical Care · doi:10.1186/cc6818 · Cited by 57
Fehér, C., Rovira, M., Soriano, À., Esteve, J., Martínez, J. A., Marco, F., Carreras, E., Martínez, C., Fernández‐Avilés, F., Suárez‐Lledó, M., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku150 · Cited by 53
Treatment of gram-negative bacillary septicemia with cefoperazone
Lagast, H., Meunier-Carpentier, F., & Klastersky, J. A. (1983) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02016564 · Cited by 51
Lal, A., Jaoude, P., & El-Solh, A. A. (2016) · Infection & Chemotherapy · doi:10.3947/ic.2016.48.2.81 · Cited by 44
Evaluating Outcomes of Alternative Dosing Strategies for Cefepime: A Qualitative Systematic Review
Burgess, S. V., Mabasa, V. H., Chow, I., & Ensom, M. H. H. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564179 · Cited by 38
Perrott, J. L., Mabasa, V. H., & Ensom, M. H. H. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m339 · Cited by 38
Continuous and Extended Infusions of β-Lactam Antibiotics in the Pediatric Population
Walker, M. C., Lam, W. M., & Manasco, K. B. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r216 · Cited by 35
Yusuf, E., Spapen, H. D., & Piérard, D. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.07.033 · Cited by 34
Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis
Korbila, I. P., Tansarli, G. S., Karageorgopoulos, D. E., Vardakas, K. Z., & Falagas, M. E. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.44 · Cited by 30
Mah, G. T., Mabasa, V. H., Chow, I., & Ensom, M. H. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q378 · Cited by 26
Wang, Z., Shan, T., Liu, Y., Ding, S., Li, C., Zhai, Q., Chen, X., Du, B., Li, Y., Zhang, J., et al. (2014) · PubMed · doi:10.3760/cma.j.issn.2095-4352.2014.09.008 · Cited by 16
Yang, H., Cui, X., Ma, Z., & Liu, L. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps.v19i2.27517 · Cited by 15
Yang, H., Cui, X., Ma, Z., & Liu, L. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j33s4b · Cited by 11
Lux, L. J., Posey, R., Daniels, L. S., Henke, D. C., Durham, C. G., Jonas, D. E., & Lohr, K. N. (2014) · Europe PMC (PubMed Central) · Cited by 6
Piperacilina-tazobactam en perfusión continua o expandida frente a perfusión intermitente
Acosta-García, H., Gil-Navarro, M. V., Luque, J. C., Cisneros, J. M., Lepe, J. A., & Paloma, J. B. (2012) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.06.013 · Cited by 3
Lee, Y. R., Miller, P. D., Alzghari, S. K., Blanco, D. D., Hager, J. D., & Kuntz, K. S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0446-6 · Cited by 3
Do Prolonged Infusions of Beta Lactams Improve Clinical Cure? A Meta Analysis
Hassan, F., Aziz, N. A., Hassan, Y., Hassan, H. A., Wahab, N. S. A., Fatimah, S., Mufti, J., & Khalil, H. (2013) · International Journal of Pharmaceutical Sciences Review and Research · Cited by 1
Research works printed but not linked: 2
- Pollock M FR, Becker LA, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. www.training.cochrane.org/handbook.
- Centre for Reviews and D, 2015, Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis (Provisional abstract), Database of Abstracts of Reviews of Effects
Cited by
Lunny, C., Pieper, D., Thabet, P., & Kanji, S. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01269-y · Cited by 252
Self-citationOptimizing antibiotic therapies to reduce the risk of bacterial resistance
Bassetti, S., Tschudin-Sutter, S., Egli, A., & Osthoff, M. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.01.029 · Cited by 196
Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., et al. (2024) · JAMA · doi:10.1001/jama.2024.9779 · Cited by 171
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
Suicidality risk after using cannabis and cannabinoids: An umbrella review
Shamabadi, A., Ahmadzade, A., Pirahesh, K., Hasanzadeh, A., & Asadigandomani, H. (2023) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2023.2231466 · Cited by 51
Metadata
- Authors
- Thabet, P., Joshi, A., MacDonald, E., Hutton, B., Cheng, W., Stevens, A., & Kanji, S.
- Affiliations
- Ottawa Hospital (CA)
- University of Waterloo (CA)
- University of Ottawa (CA)
- Ottawa Hospital Research Institute (CA)
- McMaster University (CA)
- Corresponding author
- Kanji, Salmaan
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-01-22
- Volume
- 16
- Issue
- 1
- Pages
- e0244966
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7822342
- OpenAlex
- W3125727119
- Cited by
- 29
- References
- 62
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 4
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, prolonged infusion, intermittent infusion, intravenous antibiotic administration, mortality, clinical cure, microbiological cure, length of hospital stay, antimicrobial resistance, critically ill patients, pharmacokinetics, pharmacodynamics
- MeSH terms
- Systematic Reviews as Topic, Anti-Bacterial Agents, Bacterial Infections, Humans, Infusions, Intravenous, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.